BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Immedica Pharma AB readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Immedica Pharma AB's drugs run\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05249556-8882@assetmemo.bio
DTSTAMP:20261121T010439Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Ganaxolone: Phase 3 readout est. (NCT05249556)
DESCRIPTION:Ganaxolone\, phase 3.\nStudy: Open-label\, Single-arm Trial of 
 Ganaxolone in CDD Patients 6 Months to Less Than 2 Years Old\nEstimated pr
 imary completion: December 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/ganaxolone#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05249556
URL:https://assetmemo.bio/drug/ganaxolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
